(UroToday.com) The 2025 ESMO annual meeting featured a metastatic castration-resistant prostate cancer (mCRPC) session and a presentation by Dr. Channing Paller discussing germline and somatic genetic ...
An international team led by Monash University researchers has uncovered the genetic code governing the way genetic mutations ...
When Homo sapiens and Neanderthals interbred, a genetic variation affecting red blood cells may have hindered reproduction in ...
For patients with HRRm prostate cancer receiving Akeega and Zytiga with prednisone, quality of life remained at baseline.
“You can see that there was an initial reduction in the HR-QOL score in the niraparib arm, which may have been explained by the onset of the most frequently observed adverse events, which included ...
Rathkopf presented the Late-breaking abstract 91 - Patient-reported outcomes (PROs) from AMPLITUDE, a randomized placebo-controlled phase 3 trial of niraparib (NIRA) and abiraterone acetate (AA) plus ...
Potential first-in-class, and industry-leading DNA polymerase Theta (Polθ) inhibitor, ART6043 demonstrated an attractive tolerability profile, expected PK/PD activity, and promising clinical ...
A conference abstract presented at the European Society for Medical Oncology (ESMO) 2025 meeting looks at prostate cancer screening in men with BRACA1 and BRACA2 mutations. Prof Alastair D Lamb, CRUK ...
The impact of IL10 mutation in birds highlights the intrinsic compromise between effective elimination of a pathogen and damage to the host.
An international study has shown how and when entirely new gene mutations, known as de novo mutations, originate in dogs. A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback